Statement: the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first day of the study.
Primary_evidence: INTERVENTION 1:    High-dose Chemotherapy   Carboplatin + Cyclophosphamide + Thiotepa   Carboplatin : Target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.   Thiotepa : 120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.   Stem Cell Transplant : Stem Cell Transplant on Day 0.   Cyclophosphamide : 1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
Secondary_evidence: INTERVENTION 1:    Samarium 153-EDTMP + Stem Cell Transplant   Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones, receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose. Stem Cell Transplant Day 0, about 14-21 days after Samarium 153-EDTMP.